# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-092720
Filing Date
2024-08-07
Accepted
2024-08-07 16:01:32
Documents
86
Period of Report
2024-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | srpt-20240630.htm iXBRL | 10-Q | 3421794
2 | EX-31.1 | srpt-ex31_1.htm | EX-31.1 | 11739
3 | EX-31.2 | srpt-ex31_2.htm | EX-31.2 | 11790
4 | EX-32.1 | srpt-ex32_1.htm | EX-32.1 | 8027
5 | EX-32.2 | srpt-ex32_2.htm | EX-32.2 | 7956
| Complete submission text file | 0000950170-24-092720.txt |  | 11942784

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
6 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | srpt-20240630.xsd | EX-101.SCH | 1409422
88 | EXTRACTED XBRL INSTANCE DOCUMENT | srpt-20240630_htm.xml | XML | 2286325

Mailing Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142
Business Address 215 FIRST STREET SUITE 415 CAMBRIDGE MA 02142 617-274-4000
Sarepta Therapeutics, Inc. (Filer) CIK: 0000873303 (see all company filings)

EIN.: 930797222 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-14895 | Film No.: 241183456
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)